Peptide name : Apo E

Source/Organism : Apoprotein E

Linear/Cyclic : Linear

Chirality : L

Peptide length: 30

C-terminal modification: Linear

N-terminal modification : Free

Non-natural peptide information: None

Assay type : MTT/MTS assay

Assay time : 4h

Activity : 55 % Cytotoxity at 40 µg/ml

Cell line : Paca-2

Cancer type : Pancreatic cancer

Other activity : Not found

Amino acid composition bar chart :

Molecular mass : 3673.3698 Dalton

Aliphatic index : 1.333

Instability index : 59.7733

Hydrophobicity (GRAVY) : -0.61

Isoelectric point : 11.629

Charge (pH 7) : 6.8466

Aromaticity : 0.033

Molar extinction coefficient (cysteine, cystine): (1490, 1490)

Hydrophobic/hydrophilic ratio : 0.76470588

hydrophobic moment : 0.1891

Missing amino acid : C,W,T,P,M,I,E,F,N,G

Most occurring amino acid : L

Most occurring amino acid frequency : 8

Least occurring amino acid : S

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (0.4, 0.1, 0.3)

SMILES Notation: CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(C)C)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)C(C)C

1 : Kojima T, et al. Anti-tumor activity of an antibiotic peptide derived from apoprotein E. In Vivo. 2005; 19:261-4.

Paper title : Anti-tumor activity of an antibiotic peptide derived from apoprotein E.

Doi : https://doi.org/Not available

Abstract : BACKGROUND: Recently, we found that a 30-mer peptide derived from apoprotein E (apoE) 133-162 has antibiotic activity that is comparable with the classic antibiotics and neutrophil-derived antibiotic peptide. In this study, we tested if apoE 133-162 also has anti-tumor activity against several cancer cell lines. MATERIALS AND METHODS: Two gastric cancer cell lines (MKN-7, MNN-1), two pancreatic cancer cell lines (PANC-1, Paca-2) and one colon cancer cell line (COLO201) were used for MTT cytotoxic assay. Calcein leakage from artificial liposomes was also tested, varying the composition of liposome. RESULTS: The apoE 133-162 peptide had cytotoxic activity against all tested human cancer cell lines in a dose-dependent manner. In the Paca-2 cell, an equivalent cytotoxic activity to 5-FU (10 microg/ml) was observed at about 40 microg/ml of apoE 133-162 peptide, but no synergistic effect of apoE 133-162 (40 microg/ml ) with 5-FU (10 microg/ml), nor inhibitory effect by heparin(100 microg/ml), was observed. In the calcein leakage test, in the presence of 150 mM NaCl, the presence of cholesterol attenuated the membrane perturbation activity of apoE 133-162, and the more acidic membrane was susceptible to lysis. CONCLUSION: ApoE 133-162 has anti-tumor activity, probably through perturbation and formation of ion-permeable "pores" in membranes.